Discontinued — last reported Q4 '16
Short-Term Investments
Alnylam Pharmaceuticals Short-Term Investments increased by 3.8% to $1.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 19.1%, from $1.61B to $1.30B. Over 5 years (FY 2020 to FY 2025), Short-Term Investments shows relatively stable performance with a -1.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher levels indicate strong liquidity and significant 'dry powder' for acquisitions or R&D, while lower levels might suggest cash is being deployed into long-term projects or shareholder returns.
Detailed definition
Highly liquid assets and marketable securities that are expected to be converted into cash within one year. For technolo...
Peer comparison
Commonly compared against other cash-rich technology peers to assess capital preservation strategies and short-term solvency.
short_term_investmentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.10B | $1.16B | $1.55B | $1.67B | $1.50B | $1.17B | $1.30B | $1.37B | $1.37B | $1.36B | $1.62B | $1.68B | $1.65B | $1.67B | $1.72B | $1.61B | $1.74B | $1.23B | $1.25B | $1.30B |
| QoQ Change | — | +5.4% | +33.3% | +8.1% | -10.1% | -22.3% | +11.0% | +5.8% | -0.0% | -0.7% | +18.5% | +3.9% | -1.9% | +1.6% | +2.9% | -6.7% | +8.6% | -29.2% | +1.4% | +3.8% |
| YoY Change | — | — | — | — | +36.5% | +0.7% | -16.2% | -18.0% | -8.8% | +16.6% | +24.5% | +22.3% | +20.0% | +22.7% | +6.5% | -4.3% | +5.9% | -26.2% | -27.3% | -19.1% |
Short-Term Investments at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's short-term investments?
- Alnylam Pharmaceuticals (ALNY) reported short-term investments of $1.30B in Q1 2026.
- How has Alnylam Pharmaceuticals's short-term investments changed year-over-year?
- Alnylam Pharmaceuticals's short-term investments decreased by 19.1% year-over-year, from $1.61B to $1.30B.
- What is the long-term trend for Alnylam Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's short-term investments has grown at a -1.3% compound annual growth rate (CAGR), from $1.33B to $1.25B.
- What does short-term investments mean?
- Investments like stocks or bonds that the company plans to sell or cash out within the next twelve months.